B. Riley took over coverage of X4 Pharmaceuticals with a Buy rating and $3 price target. The firm’s investment thesis is based on the potential success of the company’s leading asset, mavorixafor, for treating chronic neutropenia and Whim syndrome. The analyst believes the stock has been “irrationally penalized following the promising” new data in chronic neutropenia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on XFOR:
- X4 Pharmaceuticals files $300M mixed securities shelf
- X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program
- X4 Pharmaceuticals reports Q2 EPS (33c), consensus (16c)
- XFOR Upcoming Earnings Report: What to Expect?
- X4 Pharmaceuticals closes $115M loan facility with Hercules Capital